These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. Chan CW; Gunsar F; Feudjo M; Rigamonti C; Vlachogiannakos J; Carpenter JR; Burroughs AK Aliment Pharmacol Ther; 2005 Feb; 21(3):217-26. PubMed ID: 15691295 [TBL] [Abstract][Full Text] [Related]
7. Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. Invernizzi P; Setchell KD; Crosignani A; Battezzati PM; Larghi A; O'Connell NC; Podda M Hepatology; 1999 Feb; 29(2):320-7. PubMed ID: 9918905 [TBL] [Abstract][Full Text] [Related]
8. Antifibrotic therapy of liver cirrhosis, with special reference to primary biliary cirrhosis: promises and limitations. Jansen PL Neth J Med; 1992 Apr; 40(3-4):209-14. PubMed ID: 1603214 [No Abstract] [Full Text] [Related]
9. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents. Silveira MG; Lindor KD Clin Liver Dis; 2008 May; 12(2):425-43; x-xi. PubMed ID: 18456189 [TBL] [Abstract][Full Text] [Related]
11. [Infrequent but serious: autoimmune hepatitis and primary biliary cirrhosis. Early therapy improves long-term prognosis]. MMW Fortschr Med; 2008 Apr; 150(15):45. PubMed ID: 18510120 [No Abstract] [Full Text] [Related]
12. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904 [TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholic acid and long-term survival in primary biliary cirrhosis. Levy C; Angulo P Am J Gastroenterol; 2004 Feb; 99(2):269-70. PubMed ID: 15046216 [No Abstract] [Full Text] [Related]
14. [Ursodeoxycholic acid in primary biliary cirrhosis. 2: Prospective long-term study of 21 patients]. Eisenburg J; Eder M; Spengler U; Berg PA; Caselmann W; Mannes AG; Muntau A Fortschr Med; 1988 Nov; 106(34):695-8. PubMed ID: 3145247 [No Abstract] [Full Text] [Related]
15. [What is guaranteed in the therapy of primary biliary cirrhosis with bile acids?]. Leuschner U Internist (Berl); 1990 Nov; 31(11):707-11. PubMed ID: 2289857 [No Abstract] [Full Text] [Related]
17. [Ursodeoxycholic acid therapy in biliary cirrhosis]. Herszényi L; Szalay L; Schaff Z; Gergely P; Fehér J Orv Hetil; 1993 Sep; 134(38):2085-9. PubMed ID: 8414454 [TBL] [Abstract][Full Text] [Related]
18. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Walker LJ; Newton J; Jones DE; Bassendine MF Hepatology; 2009 Jan; 49(1):337-8; author reply 338. PubMed ID: 19035342 [No Abstract] [Full Text] [Related]
19. The long-term beneficial effects of ursodeoxycholic acid in primary biliary cirrhosis are highly questionable. Yan G; Erik C; Gluud C Am J Gastroenterol; 2007 Feb; 102(2):464-5. PubMed ID: 17311669 [No Abstract] [Full Text] [Related]
20. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy. Babatin MA; Sanai FM; Swain MG Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]